Literature DB >> 22232210

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

Evita van de Steeg1, Viktor Stránecký, Hana Hartmannová, Lenka Nosková, Martin Hřebíček, Els Wagenaar, Anita van Esch, Dirk R de Waart, Ronald P J Oude Elferink, Kathryn E Kenworthy, Eva Sticová, Mohammad al-Edreesi, A S Knisely, Stanislav Kmoch, Milan Jirsa, Alfred H Schinkel.   

Abstract

Bilirubin, a breakdown product of heme, is normally glucuronidated and excreted by the liver into bile. Failure of this system can lead to a buildup of conjugated bilirubin in the blood, resulting in jaundice. The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3. These important detoxification-limiting proteins mediate uptake and clearance of countless drugs and drug conjugates across the sinusoidal hepatocyte membrane. OATP1B1 polymorphisms have previously been linked to drug hypersensitivities. Using mice deficient in Oatp1a/1b and in the multispecific sinusoidal export pump Abcc3, we found that Abcc3 secretes bilirubin conjugates into the blood, while Oatp1a/1b transporters mediate their hepatic reuptake. Transgenic expression of human OATP1B1 or OATP1B3 restored the function of this detoxification-enhancing liver-blood shuttle in Oatp1a/1b-deficient mice. Within liver lobules, this shuttle may allow flexible transfer of bilirubin conjugates (and probably also drug conjugates) formed in upstream hepatocytes to downstream hepatocytes, thereby preventing local saturation of further detoxification processes and hepatocyte toxic injury. Thus, disruption of hepatic reuptake of bilirubin glucuronide due to coexisting OATP1B1 and OATP1B3 deficiencies explains Rotor-type hyperbilirubinemia. Moreover, OATP1B1 and OATP1B3 null mutations may confer substantial drug toxicity risks.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22232210      PMCID: PMC3266790          DOI: 10.1172/JCI59526

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

Authors:  Evita van de Steeg; Els Wagenaar; Cornelia M M van der Kruijssen; Johanna E C Burggraaff; Dirk R de Waart; Ronald P J Oude Elferink; Kathryn E Kenworthy; Alfred H Schinkel
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

2.  Interaction of porphyrins with human organic anion transporting polypeptide 1B1.

Authors:  Scott D Campbell; Wan F Lau; Jinghai J Xu
Journal:  Chem Biol Interact       Date:  2009-06-26       Impact factor: 5.192

3.  A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane.

Authors:  J König; Y Cui; A T Nies; D Keppler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-01       Impact factor: 4.052

4.  Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide.

Authors:  J König; Y Cui; A T Nies; D Keppler
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

Review 5.  Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).

Authors:  Christian P Strassburg
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-10       Impact factor: 3.043

Review 6.  Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family.

Authors:  B Hagenbuch; C Gui
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

7.  Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Authors:  Lisa R Treviño; Noriko Shimasaki; Wenjian Yang; John C Panetta; Cheng Cheng; Deqing Pei; Diana Chan; Alex Sparreboom; Kathleen M Giacomini; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

Review 8.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

9.  Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies.

Authors:  Giulia Ghibellini; Elaine M Leslie; Gary M Pollack; Kim L R Brouwer
Journal:  Pharm Res       Date:  2008-05-30       Impact factor: 4.200

10.  Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia.

Authors:  Serena Sanna; Fabio Busonero; Andrea Maschio; Patrick F McArdle; Gianluca Usala; Mariano Dei; Sandra Lai; Antonella Mulas; Maria Grazia Piras; Lucia Perseu; Marco Masala; Mara Marongiu; Laura Crisponi; Silvia Naitza; Renzo Galanello; Gonçalo R Abecasis; Alan R Shuldiner; David Schlessinger; Antonio Cao; Manuela Uda
Journal:  Hum Mol Genet       Date:  2009-05-06       Impact factor: 6.150

View more
  87 in total

Review 1.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

2.  Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines.

Authors:  Satoki Imai; Ryota Kikuchi; Yuri Tsuruya; Sotaro Naoi; Sho Nishida; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2013-06-28       Impact factor: 4.200

Review 3.  Bilirubin in the Liver-Gut Signaling Axis.

Authors:  Abdul-Rizaq Hamoud; Lauren Weaver; David E Stec; Terry D Hinds
Journal:  Trends Endocrinol Metab       Date:  2018-02-03       Impact factor: 12.015

4.  Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.

Authors:  Hiroko Sato; Toshihiko Uchida; Kentaro Toyota; Tomohiro Nakamura; Gen Tamiya; Miyako Kanno; Taeko Hashimoto; Masashi Watanabe; Kuraaki Aoki; Kiyoshi Hayasaka
Journal:  J Hum Genet       Date:  2014-11-13       Impact factor: 3.172

5.  2016 Presidential Address: Let's Make Human Genetics Great (Again): The Importance of Beauty in Science.

Authors:  Harry C Dietz
Journal:  Am J Hum Genet       Date:  2017-03-02       Impact factor: 11.025

6.  ATP11C targets basolateral bile salt transporter proteins in mouse central hepatocytes.

Authors:  Dirk R de Waart; Jyoti Naik; Karina S Utsunomiya; Suzanne Duijst; Kam Ho-Mok; A Ruth Bolier; Johan Hiralall; Laura N Bull; Piter J Bosma; Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Hepatology       Date:  2016-04-06       Impact factor: 17.425

Review 7.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

8.  Not all (bile acids) who wander are lost: the first report of a patient with an isolated NTCP defect.

Authors:  Saul J Karpen; Paul A Dawson
Journal:  Hepatology       Date:  2014-11-20       Impact factor: 17.425

Review 9.  Gene replacement therapy for genetic hepatocellular jaundice.

Authors:  Remco van Dijk; Ulrich Beuers; Piter J Bosma
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 10.  Inherited disorders of bilirubin clearance.

Authors:  Naureen Memon; Barry I Weinberger; Thomas Hegyi; Lauren M Aleksunes
Journal:  Pediatr Res       Date:  2015-11-23       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.